IFP Advisors’s Cue Biopharma CUE Stock Holding History

IFP Advisors’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$78	Sell	3 -100	-97%	-$2.97K	﹤0.01%	5012
2026 Q2	$150	Buy	103 +100	+3,333%	+$2.26K	﹤0.01%	4903
2026 Q1	$23	Hold	3	–	–	﹤0.01%	4908
2025 Q4	$31	Hold	3	–	–	﹤0.01%	4759
2025 Q3	$72	Hold	3	–	–	﹤0.01%	4597
2025 Q2	$68	Hold	3	–	–	﹤0.01%	4777
2025 Q1	$91	Hold	3	–	–	﹤0.01%	3877
2024 Q4	$109	Hold	3	–	–	﹤0.01%	4002
2024 Q3	$76	Hold	3	–	–	﹤0.01%	3244
2024 Q2	$124	Hold	3	–	–	﹤0.01%	3162
2024 Q1	$189	Hold	3	–	–	﹤0.01%	3033
2023 Q4	$264	Buy	+3	New	+$214	﹤0.01%	2922

Other funds holding CUE

Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return

Gleason Group Prospect, Kentucky $1.13B AUM 12.68% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return

Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

IFP Advisors's CUE Position: Q3 2026 in Review

IFP Advisors reduced its Cue Biopharma (CUE) stake by 97% in Q3 2026, selling an estimated $2.97K and leaving 3 shares worth $78. The position accounts for ﹤0.01% of the portfolio, ranked #5012.

IFP Advisors first reported a position in CUE in Q4 2023 and has held it in 12 quarters since. The position peaked at $264 in Q4 2023. 6 funds tracked by Wall St. Rank hold CUE as of Q3 2026.

IFP Advisors held 3 shares of Cue Biopharma worth $78 as of Q3 2026.
IFP Advisors sold 100 Cue Biopharma shares in Q3 2026, an estimated $2.97K.
Cue Biopharma made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #5012 holding.
IFP Advisors first reported a position in Cue Biopharma in Q4 2023 and has held it in 12 quarters since.
IFP Advisors's Cue Biopharma position peaked at $264 in Q4 2023.
6 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.